vs

Side-by-side financial comparison of Alector, Inc. (ALEC) and BTCS Inc. (BTCS). Click either name above to swap in a different company.

BTCS Inc. is the larger business by last-quarter revenue ($7.1M vs $6.2M, roughly 1.1× Alector, Inc.). On growth, BTCS Inc. posted the faster year-over-year revenue change (205.5% vs -88.5%). BTCS Inc. produced more free cash flow last quarter ($-9.8M vs $-184.1M). Over the past eight quarters, BTCS Inc.'s revenue compounded faster (296.4% CAGR vs -37.4%).

Alector, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative immunotherapies for neurodegenerative diseases. Its product pipeline targets unmet medical needs including Alzheimer’s disease, frontotemporal dementia, and Parkinson’s disease, and it collaborates with global pharmaceutical partners to advance candidate therapies through clinical trials.

ALEC vs BTCS — Head-to-Head

Bigger by revenue
BTCS
BTCS
1.1× larger
BTCS
$7.1M
$6.2M
ALEC
Growing faster (revenue YoY)
BTCS
BTCS
+294.0% gap
BTCS
205.5%
-88.5%
ALEC
More free cash flow
BTCS
BTCS
$174.3M more FCF
BTCS
$-9.8M
$-184.1M
ALEC
Faster 2-yr revenue CAGR
BTCS
BTCS
Annualised
BTCS
296.4%
-37.4%
ALEC

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
ALEC
ALEC
BTCS
BTCS
Revenue
$6.2M
$7.1M
Net Profit
Gross Margin
12.4%
Operating Margin
Net Margin
Revenue YoY
-88.5%
205.5%
Net Profit YoY
-1696.9%
EPS (diluted)
$-1.58

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ALEC
ALEC
BTCS
BTCS
Q4 25
$6.2M
$7.1M
Q3 25
$3.3M
$4.9M
Q2 25
$7.9M
$2.8M
Q1 25
$3.7M
$1.7M
Q4 24
$54.2M
$2.3M
Q3 24
$15.3M
$739.2K
Q2 24
$15.1M
$561.2K
Q1 24
$15.9M
$451.4K
Net Profit
ALEC
ALEC
BTCS
BTCS
Q4 25
Q3 25
$-34.7M
$65.6M
Q2 25
$-30.5M
$3.9M
Q1 25
$-40.5M
$-17.3M
Q4 24
$-2.1M
Q3 24
$-42.2M
$-9.0M
Q2 24
$-38.7M
$-6.7M
Q1 24
$-36.1M
$12.3M
Gross Margin
ALEC
ALEC
BTCS
BTCS
Q4 25
12.4%
Q3 25
22.0%
Q2 25
-2.9%
Q1 25
7.1%
Q4 24
2.9%
Q3 24
26.5%
Q2 24
69.9%
Q1 24
64.4%
Operating Margin
ALEC
ALEC
BTCS
BTCS
Q4 25
Q3 25
-1153.6%
Q2 25
-433.6%
Q1 25
-1216.5%
Q4 24
-13.4%
Q3 24
-315.7%
Q2 24
-302.4%
Q1 24
-275.0%
Net Margin
ALEC
ALEC
BTCS
BTCS
Q4 25
Q3 25
-1063.4%
1328.1%
Q2 25
-387.7%
140.0%
Q1 25
-1101.6%
-1022.5%
Q4 24
-3.8%
Q3 24
-275.2%
-1223.0%
Q2 24
-256.4%
-1198.9%
Q1 24
-227.0%
2715.3%
EPS (diluted)
ALEC
ALEC
BTCS
BTCS
Q4 25
$-1.58
Q3 25
$-0.34
$1.30
Q2 25
$-0.30
$0.14
Q1 25
$-0.41
$-0.86
Q4 24
$-0.02
$0.28
Q3 24
$-0.43
$-0.56
Q2 24
$-0.40
$-0.43
Q1 24
$-0.38
$0.63

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ALEC
ALEC
BTCS
BTCS
Cash + ST InvestmentsLiquidity on hand
$256.0M
$1.5M
Total DebtLower is stronger
$10.0M
Stockholders' EquityBook value
$30.6M
$139.4M
Total Assets
$293.2M
$214.6M
Debt / EquityLower = less leverage
0.33×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ALEC
ALEC
BTCS
BTCS
Q4 25
$256.0M
$1.5M
Q3 25
$291.1M
$4.5M
Q2 25
$307.3M
$639.2K
Q1 25
$354.6M
$269.9K
Q4 24
$413.4M
$2.0M
Q3 24
$457.2M
$254.5K
Q2 24
$503.3M
$536.7K
Q1 24
$562.1M
$670.6K
Total Debt
ALEC
ALEC
BTCS
BTCS
Q4 25
$10.0M
Q3 25
Q2 25
Q1 25
Q4 24
$10.0M
Q3 24
Q2 24
Q1 24
Stockholders' Equity
ALEC
ALEC
BTCS
BTCS
Q4 25
$30.6M
$139.4M
Q3 25
$57.7M
$225.4M
Q2 25
$71.2M
$31.1M
Q1 25
$94.6M
$20.6M
Q4 24
$126.8M
$34.0M
Q3 24
$118.9M
$25.2M
Q2 24
$150.6M
$33.1M
Q1 24
$178.9M
$39.3M
Total Assets
ALEC
ALEC
BTCS
BTCS
Q4 25
$293.2M
$214.6M
Q3 25
$335.3M
$298.9M
Q2 25
$356.4M
$40.8M
Q1 25
$408.3M
$21.0M
Q4 24
$468.3M
$38.2M
Q3 24
$516.0M
$26.5M
Q2 24
$570.7M
$33.8M
Q1 24
$635.5M
$39.5M
Debt / Equity
ALEC
ALEC
BTCS
BTCS
Q4 25
0.33×
Q3 25
Q2 25
Q1 25
Q4 24
0.08×
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ALEC
ALEC
BTCS
BTCS
Operating Cash FlowLast quarter
$-184.0M
$-9.8M
Free Cash FlowOCF − Capex
$-184.1M
$-9.8M
FCF MarginFCF / Revenue
-2951.3%
-138.1%
Capex IntensityCapex / Revenue
0.7%
0.2%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-326.5M
$-15.8M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ALEC
ALEC
BTCS
BTCS
Q4 25
$-184.0M
$-9.8M
Q3 25
$-32.5M
$-2.8M
Q2 25
$-49.0M
$-1.3M
Q1 25
$-60.8M
$-1.9M
Q4 24
$-55.0M
$-3.5M
Q3 24
$-50.7M
$-695.2K
Q2 24
$-62.8M
$-924.1K
Q1 24
$-61.3M
$-769.0K
Free Cash Flow
ALEC
ALEC
BTCS
BTCS
Q4 25
$-184.1M
$-9.8M
Q3 25
$-32.5M
$-2.8M
Q2 25
$-49.1M
$-1.3M
Q1 25
$-60.8M
$-1.9M
Q4 24
$-55.2M
$-3.5M
Q3 24
$-50.9M
Q2 24
$-63.1M
Q1 24
$-61.9M
FCF Margin
ALEC
ALEC
BTCS
BTCS
Q4 25
-2951.3%
-138.1%
Q3 25
-997.6%
-56.7%
Q2 25
-623.0%
-48.2%
Q1 25
-1655.0%
-112.7%
Q4 24
-101.8%
-152.2%
Q3 24
-332.1%
Q2 24
-418.6%
Q1 24
-389.3%
Capex Intensity
ALEC
ALEC
BTCS
BTCS
Q4 25
0.7%
0.2%
Q3 25
0.3%
0.1%
Q2 25
0.1%
0.1%
Q1 25
0.5%
0.1%
Q4 24
0.3%
0.1%
Q3 24
1.4%
Q2 24
2.2%
Q1 24
3.4%
Cash Conversion
ALEC
ALEC
BTCS
BTCS
Q4 25
Q3 25
-0.04×
Q2 25
-0.34×
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
-0.06×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ALEC
ALEC

Segment breakdown not available.

BTCS
BTCS

Builder Plus$5.9M83%
Other$1.2M17%

Related Comparisons